# PleoPharma Awarded $6.5 Million NIDA Grant to Support Phase 3 Trial of PP-01 for … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pleopharma-awarded-6-5-million-nida-grant-to-support-phase-3-trial-of-pp-01-for/ > **Published:** 2026-08-20T12:13:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:16:06-04:00 > **Clinical Summary:** NIDA-funded Phase 3 trial of PP-01 for cannabis withdrawal pharmacotherapy. What clinicians need to know about this first-in-class development. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyPainAnxietyMental HealthIndustryNeurology Why This Matters This NIDA-funded Phase 3 trial represents progress toward a FDA-approved pharmacological treatment for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), which currently lacks medications and affects millions of patients. Clinical validation of PP-01 could provide clinicians with an evidence-based pharmacotherapy option to offer patients struggling with [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/), particularly those with moderate to severe use disorder. Success in this trial may establish a standard treatment pathway that improves outcomes for patients unable to achieve abstinence through behavioral interventions alone. Clinical Summary PleoPharma has received a $6.5 million grant from the National Institute on Drug Abuse to advance its Phase 3 clinical trial (CAN-004) evaluating PP-01, an investigational pharmacotherapy for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). This funding represents a significant commitment to developing evidence-based pharmaceutical treatment options for a condition affecting millions of Americans, particularly as cannabis potency and availability continue to increase. The Phase 3 trial will provide rigorous clinical data on PP-01’s efficacy and safety profile, which is essential for potential FDA approval and subsequent clinical integration. A successful outcome could offer physicians a validated pharmacological tool to complement existing behavioral interventions for patients struggling with [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/), addressing a currently underserved treatment gap in [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/). Clinicians should monitor the progression of this trial, as positive results may expand the therapeutic armamentarium for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and improve treatment outcomes for affected patients. Dr. Caplan’s Take “This is encouraging news for the field, but we need to be clear about where we are in the development pipeline. Phase 3 trials are rigorous and essential, but they’re not the finish line, and federal funding doesn’t yet tell us whether PP-01 will actually prove safe and effective in the patient populations that need it most.” Clinical Perspective 💊 PleoPharma’s federally funded Phase 3 trial of PP-01 represents a meaningful step toward developing a pharmacological intervention for cannabis use disorder, a condition affecting millions yet lacking FDA-approved medications. While this grant reflects growing recognition by the National Institute on Drug Abuse that pharmaceutical approaches warrant investigation, clinicians should note that preclinical efficacy does not guarantee clinical benefit, and [cannabinoid pharmacology](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) remains incompletely understood due to decades of research constraints. The heterogeneity of cannabis use patterns, potency variations in street products, and individual differences in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/) all represent confounders that could complicate trial interpretation and downstream clinical applicability. Until robust Phase 3 data emerge, current standard care for cannabis use disorder continues to rely on behavioral interventions, motivational enhancement, and cognitive-behavioral therapy, which providers should offer as first-line approaches. As this trial progresses, clinicians may consider enroll 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20PleoPharma%20Awarded%20%246.5%20Million%20NIDA%20Grant%20to%20Support%20Phase%203%20Trial%20of%20PP-01%20for%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74407)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74407)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20PleoPharma%20Awarded%20%246.5%20Million%20NIDA%20Grant%20to%20Support%20Phase%203%20Trial%20of%20PP-01%20for%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74407)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.prnewswire.com/news-releases/pleopharma-awarded-6-5-million-nida-grant-to-support-phase-3-trial-of-pp-01-for-cannabis-withdrawal-in-patients-with-cannabis-use-disorder-302856379.html](https://www.prnewswire.com/news-releases/pleopharma-awarded-6-5-million-nida-grant-to-support-phase-3-trial-of-pp-01-for-cannabis-withdrawal-in-patients-with-cannabis-use-disorder-302856379.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).